includes a"monoclonal antibody that targets the spike protein the virus uses to drill into healthy cells, and another antibody that targets a different part of the novel coronavirus." The goal of the drug is to stop the virus from replicating.
On Sept. 29, Regeneron released early test results that involved only 245 patients indicating that the cocktail appeared to reduce levels of the virus, improve symptoms, and lower medical visits for patients, CNN reported. Jeanne Marrazzo, MD, director of the division of infectious diseases at University of Alabama at Birmingham, told CNN that the results of the trial seem"very promising," yet the data hasn't been peer reviewed..
where he said,"I think I'm doing very well, but we're going to make sure that things work out." He also noted that the first lady is"doing very well." POPSUGAR aims to give you the most accurate and up-to-date information about the coronavirus, but details and recommendations about this pandemic may have changed since publication. For the latest information on COVID-19, please check out resources from the
But how do we KNOW this? Who’s to say he isn’t in bed with big pharma and pushing the vaccine agenda?
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.